Skip to main content

Table 4 Plasma phospholipid fatty acids at baseline (week 0) and following diets that incorporated the control and modified dairy products (week 12) in adults at moderate cardiovascular disease riska

From: Plasma phospholipid fatty acid profile confirms compliance to a novel saturated fat-reduced, monounsaturated fat-enriched dairy product intervention in adults at moderate cardiovascular risk: a randomized controlled trial

  Control Modified  
mol% Baseline Post Δ Baseline Post Δ p b
SFAs
 11:0 0.0000 ± 0.0008 0.0013 ± 0.0008 0.0000 ± 0.0011 0.0000 ± 0.0011 0.0002 ± 0.0000 0.0025 ± 0.0010 0.35
 12:0 0.0230 ± 0.0018 0.0242 ± 0.0015 0.0012 ± 0.0019 0.0245 ± 0.0000 0.0225 ± 0.0000 0.0019 ± 0.0016 0.22
 13:0 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.16
 14:0 0.35 ± 0.01 0.42 ± 0.02 0.07 ± 0.02 0.35 ± 0.02 0.38 ± 0.02 0.03 ± 0.01 0.04
 15:0 0.23 ± 0.01 0.26 ± 0.01 0.04 ± 0.01 0.22 ± 0.01 0.24 ± 0.01 0.02 ± 0.01 0.02
 16:0 30.70 ± 0.16 30.86 ± 0.17 0.16 ± 0.13 30.78 ± 0.13 30.32 ± 0.13 −0.46 ± 0.15 <0.001
 17:0 0.39 ± 0.01 0.40 ± 0.01 0.01 ± 0.01 0.38 ± 0.01 0.38 ± 0.01 0.00 ± 0.01 0.03
 18:0 13.95 ± 0.18 13.67 ± 0.14 −0.29 ± 0.12 14.05 ± 0.12 13.83 ± 0.12 −0.22 ± 0.13 0.33
 20:0 0.14 ± 0.00 0.13 ± 0.00 −0.01 ± 0.00 0.13 ± 0.00 0.12 ± 0.00 −0.01 ± 0.00 0.76
 21:0 0.0128 ± 0.0037 0.0130 ± 0.0043 0.0001 ± 0.0036 0.0093 ± 0.0000 0.0147 ± 0.0000 0.0054 ± 0.0034 0.62
 22:0 0.23 ± 0.01 0.22 ± 0.01 −0.01 ± 0.01 0.22 ± 0.01 0.22 ± 0.01 0.00 ± 0.01 0.69
 23:0 0.10 ± 0.00 0.11 ± 0.00 0.01 ± 0.00 0.10 ± 0.00 0.11 ± 0.00 0.01 ± 0.00 0.34
 24:0 0.25 ± 0.01 0.25 ± 0.01 0.00 ± 0.01 0.25 ± 0.01 0.24 ± 0.01 −0.01 ± 0.01 0.85
 Total SFAc 46.37 ± 0.17 46.36 ± 0.13 0.01 ± 0.17 46.52 ± 0.21 45.92 ± 0.15 −0.60 ± 0.21 0.006
MUFAs
 18:1 cis-9 9.81 ± 0.15 9.98 ± 0.16 0.17 ± 0.15 9.99 ± 0.15 10.93 ± 0.15 0.93 ± 0.19 <0.0001
 18:1 trans-9 0.08 ± 0.00 0.08 ± 0.00 0.01 ± 0.00 0.07 ± 0.00 0.17 ± 0.00 0.10 ± 0.01 <0.0001
 22:1 cis-9 0.0202 ± 0.0037 0.0206 ± 0.0030 0.0004 ± 0.0045 0.0182 ± 0.0000 0.0201 ± 0.0000 0.0000 ± 0.0019 0.52
 Total cis-MUFAd 11.02 ± 0.16 11.24 ± 0.17 0.21 ± 0.15 11.21 ± 0.18 12.20 ± 0.23 0.99 ± 0.20 <0.0001
 Total trans-MUFAe 0.12 ± 0.00 0.12 ± 0.00 0.01 ± 0.00 0.10 ± 0.00 0.23 ± 0.01 0.12 ± 0.01 <0.0001
PUFAs
 18:2 n-6 22.26 ± 0.42 22.40 ± 0.37 0.14 ± 0.28 22.00 ± 0.28 22.29 ± 0.28 0.30 ± 0.29 0.87
 18:3 n-6 0.08 ± 0.01 0.10 ± 0.01 0.02 ± 0.01 0.09 ± 0.01 0.09 ± 0.01 0.00 ± 0.01 0.51
 18:3 n-3 0.31 ± 0.02 0.31 ± 0.01 0.00 ± 0.01 0.31 ± 0.01 0.29 ± 0.01 −0.02 ± 0.01 0.58
 20:3 n-6 3.07 ± 0.08 3.39 ± 0.11 0.32 ± 0.07 3.12 ± 0.07 3.17 ± 0.07 0.06 ± 0.06 0.007
 20:4 n-6 9.88 ± 0.27 9.53 ± 0.22 −0.35 ± 0.13 9.77 ± 0.13 9.41 ± 0.13 −0.36 ± 0.21 0.74
 20:5 n-3 1.27 ± 0.08 1.25 ± 0.06 −0.02 ± 0.07 1.24 ± 0.07 1.14 ± 0.07 −0.10 ± 0.07 0.14
 22:5 n-6 0.20 ± 0.01 0.20 ± 0.01 0.00 ± 0.01 0.20 ± 0.01 0.20 ± 0.01 0.00 ± 0.01 0.17
 22:5 n-3 0.99 ± 0.03 1.02 ± 0.02 0.03 ± 0.02 1.00 ± 0.02 0.95 ± 0.02 −0.05 ± 0.03 0.55
 22:6 n-3 3.77 ± 0.16 3.39 ± 0.13 −0.37 ± 0.09 3.79 ± 0.09 3.44 ± 0.09 −0.35 ± 0.10 0.74
 Total n-3 PUFAf 5.35 ± 0.23 4.96 ± 0.17 −0.39 ± 0.14 5.34 ± 0.21 4.87 ± 0.17 −0.47 ± 0.14 0.58
 Total n-6 PUFAg 36.15 ± 0.34 36.30 ± 0.27 0.15 ± 0.26 35.83 ± 0.32 35.86 ± 0.33 0.03 ± 0.33 0.32
  1. Where no bond position is listed it is unknown [40]. 20 : 4n-6 + 20 : 3n-3 co-eluted, but as 20 : 3n-3 concentration in human samples is negligible, this peak was identified as 20 : 4n-6 [43]
  2. aValues are given as means ± SEM
  3. bOverall effect of treatment based on change-from-baseline was calculated by mixed model analysis, with adjustments made for fixed effects of baseline values of the assessed variable, period, treatment, age, gender and BMI. Participant was included as a random effect
  4. cTotal SFAs include: 11 : 0, 12 : 0, 13 : 0, 14 : 0, 15 : 0, 16 : 0, 17 : 0, 18 : 0, 20 : 0, 21 : 0, 22 : 0, 23 : 0 and 24 : 0
  5. dTotal cis-MUFAs include: 14 : 1cis, 15 : 1cis, 16 : 1cis, 17 : 1cis, 18 : 1cis-9, 20 : 1cis, 22 : 1cis-9 and 24 : 1cis. Where no bond position is listed it is unknown, as previously outlined in Wang et al. [43]
  6. eTotal trans-MUFAs include: 16 : 1trans (bond position unknown) and 18 : 1trans-9 [43]
  7. fTotal n-3 PUFAs include: 18 : 3n-3, 20 : 5n-3, 22 : 5n-3 and 22 : 6n-3
  8. gTotal n-6 PUFAs include: 18 : 2n-6, 18 : 2trans, 18 : 3n-6, 20 : 2, 20 : 3n-6, 20 : 4n-6 + 20:3n-3, 22 : 4 and 22 : 5n-6